Access the latest updates and resources from the Medicines and Healthcare Products Regulatory Agency (MHRA).
Feb 2019 - European Commission Q&A relating to the UK's withdrawal from the European Union with regard to industrial products.
This list of questions and answers gives further guidance on the basis of the Notice in a situation where the UK becomes a third country on 30 March 2019 at 00:00h (CET) ('the withdrawal date') without a ratified withdrawal agreement.
Feb 2019 - Regulating medical devices in the event of a no deal scenario
This guidance follows on from the further guidance note published on 3 January 2019. This guidance will apply from exit day subject to the The Medical Devices (amendment) (EU exit) Regulations 2019 being passed.
Jan 2019 - Further guidance note on the regulation of medicines, medical devices and clinical trials if there’s no Brexit deal
This guidance is intended to update stakeholders on the UK’s proposed arrangements for the regulation of medicines, medical devices and clinical trials, if we leave the EU on 29 March 2019 with no deal, so they can make informed plans and preparations.
Jan 2019 - MHRA releases response to consultation on EU exit no-deal legislative proposals
Following our consultation on how medicines, medical devices and clinical trials would be regulated in a no-deal scenario, we have today issued updated guidance setting out the UK’s proposed arrangements for regulation if we leave the EU on 29 March 2019 with no deal.
Aug 2018 - "What the implementation period means for the life science sector"
This update discusses how the life sciences sector would be affected by the agreement on recent developments regarding terms for an implementation period.
Aug 2018 - "Technical information on what the implementation period means for the life science sector"
This document provides more detail on the impact of recent developments on the life sciences industry.
